AlphAIalphai — Financial news for AI agents
StockHealthcare · Drug Manufacturers - General

$OGN

Organon & Co.

Price · $OGNvia TradingView
AI sentiment · 7d1 articles
MAY 20net (bullish − bearish)MAY 26
Bullish
1
Neutral
0
Bearish
0
Insider · 30dFeed →

No SEC Form 4 filings for $OGN in the last 30 days.

Top stories · $OGNMore →
MAY 21·Macau BusinessMed

Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast Asia

Hanmi Pharmaceutical has announced a partnership with Organon to export three of its combination therapies for cardiovascular and respiratory conditions to Malaysia and the Philippines. This agreement strengthens Hanmi's presence in the rapidly growing Southeast Asian pharmaceutical market, with Organon handling marketing, distribution, and sales. Both companies aim to expand treatment options and improve access to medicines in the region.

MAY 1·StockStory

Organon (NYSE:OGN) Misses Q1 CY2026 Revenue Estimates

Organon (NYSE:OGN) reported a miss on Wall Street's revenue and earnings expectations for Q1 CY2026, with sales declining 3.5% year-on-year to $1.46 billion and adjusted EPS coming in 16.8% below consensus at $0.71. The company has shown a struggle with consistent revenue growth and decreasing profitability over the past several years. Analysts anticipate revenue to remain flat and full-year EPS to grow marginally in the next 12 months, highlighting ongoing challenges for the pharmaceutical firm.

APR 30·WKYC

Organon: Q1 Earnings Snapshot

Organon & Co. (OGN) reported a first-quarter profit of $146 million, with net income of 55 cents per share. Adjusted earnings were 71 cents per share, falling short of Wall Street's expectation of 83 cents per share. The pharmaceutical company's revenue of $1.46 billion also missed analyst forecasts of $1.47 billion.

News on $OGN

All news →